"TREATMENT SUCCESS OF SOFOSBUVIR AND DACLATSVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS OF HEPATITIS C VIRUS"

Abstract

Background: To compare the frequency of responders achieving SVR12 after taking sofosbuvir and daclatasvir with vs without ribavirin.

Material and Methods:

Total 180 patients meeting inclusion criteria were enrolled in the study from Department of Medicine, Government Teaching Hospital Shahdara, Lahore.This randomized controlled trial was conducted from March 25, 2021, to September 24, 2021. Treatment naive cases were given tablet sofosbuvir & daclatasvir for 12 weeks. Treatment-experienced and naive with cirrhosis were given ribavirin based on their body weight along with sofosbuvir and daclatasvir for 12 weeks. After 3 months of treatment, patients were called for follow up at 12th week post-treatment for HCV RNA PCR to see if patient has achieved SVR12 or not. Statistical analysis was performed using SPSS v25.0. Frequency of responders was compared using the Chi-square test. P-value less than or equal to 0.05 was considered statistically significant.

Results:

In group-A, 54(60.0%) patients were males and 36(40%) patients were females. In group-B, 52(57.8%) patients were males and 38(42.2%) were females. The mean age in patients of group-A was 45.69±12.481 years while that was 44.99±14.590 years in group-B. In group-A (Sofosbuvir and daclatasvir with ribavirin), 81(90.0%) patients had a response rate and in group B (Sofosbuvir and daclatasvir), 65(72.2%) patients had a response rate with p-value (p=0.002).

Conclusion:

It was concluded that sofosbuvir & daclatasvir with ribavirin was found more efficacious than sofosbuvir & daclatasvir alone in achieving SVR 12 in patients of chronic hepatitis C infection, so it will help in delaying disease process and improving quality of life, especially in the developing world